Mechanistic role of microRNAs in coupling lipid metabolism and atherosclerosis

Advances in Experimental Medicine and Biology

Volumn 887, Issue , 2015, Pages 79-100

  Novák, Jan ^a,b   Olejníčková, Veronika ^b   Tkáčová, Nikola ^b   Santulli, Gaetano ^c  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c Department of Medicine   (United States)

Author keywords

Atherosclerosis; Cholesterol; HDL; LDL; Lipid metabolism; MiR 122; MiR 223; MiR 33

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICRORNA; MICRORNA 106A; MICRORNA 106B; MICRORNA 10B; MICRORNA 122; MICRORNA 128 2; MICRORNA 143; MICRORNA 144; MICRORNA 145; MICRORNA 19B; MICRORNA 223; MICRORNA 26; MICRORNA 27A; MICRORNA 27B; MICRORNA 302; MICRORNA 33; MICRORNA 370; MICRORNA 613; MICRORNA 758; UNCLASSIFIED DRUG; CHOLESTEROL; MIRN122 MICRORNA, HUMAN; MIRN223 MICRORNA, HUMAN; MIRN33 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ATHEROSCLEROSIS; AUTOREGULATION; CHOLESTEROL SYNTHESIS; DOWN REGULATION; ENERGY METABOLISM; EXOSOME; FATTY ACID SYNTHESIS; FEEDBACK SYSTEM; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS;

EID: 84949648072     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-22380-3_5     Document Type: Chapter

References (145)

1. Novak J, Bienertova-Vasku J, Kara T, Novak M. MicroRNAs involved in the lipid metabolism and their possible implications for atherosclerosis development and treatment. Mediators Infl amm. 2014;2014:275867
2. Santulli G. Effects of low-carbohydrate and low-fat diets. Ann Intern Med. 2015;162:392
3. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015;213:60-83
4. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology. 2008;48:1810-20
5. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331-40
6. Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol. 2002;67:491-8
7. Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13:433-44
8. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol. 2011;22:86-92
9. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol. 2009;20:363-9
10. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:289-303
11. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769-73
12. Santulli G, Iaccarino G, De Luca N, Trimarco B, Condorelli G. Atrial fi brillation and microRNAs. Front Physiol. 2014;5:15
13. Lv YC, Yin K, Fu YC, Zhang DW, Chen WJ, Tang CK. Posttranscriptional regulation of ATP-binding cassette transporter A1 in lipid metabolism. DNA Cell Biol. 2013;32:348-58
14. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identifi cation of tissue-specifi c microRNAs from mouse. Curr Biol. 2002;12:735-9
15. Sardu C, Marfella R, Santulli G, Paolisso G. Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics. 2014;15:1159-68
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116: 281-97
17. Santulli G, Wronska A, Uryu K, Diacovo TG, Gao M, Marx SO, et al. A selective microRNAbased strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014;124: 4102-14
18. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR- 33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010;285:33652-61
19. Goedeke L, Vales-Lara FM, Fenstermaker M, Cirera-Salinas D, Chamorro-Jorganes A, Ramirez CM, et al. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol. 2013;33:2339-52
20. Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microRNA: traffi cking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13(1):17-24
21. Kinet V, Halkein J, Dirkx E, Windt LJ. Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet. 2013; 4:214
22. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87-98
23. Jopling C. Liver-specifi c microRNA-122: biogenesis and function. RNA Biol. 2012;9:137-42
24. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced effi cacy by host RNA insertion or mutations in the HCV 5’ UTR. Proc Natl Acad Sci U S A. 2011;108:4991-6
25. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884-97
26. Wagner J, Riwanto M, Besler C, Knau A, Fichtlscherer S, Roxe T, et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol. 2013;33:1392-400
27. Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood. 2013;121:984-95
28. Halkein J, De Windt LJ. miR-223: sailing to terra incognita for microRNAs in platelets. Thromb Haemost. 2013;110:1112-3
29. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res. 2010;51:1513-23
30. Yang M, Liu W, Pellicane C, Sahyoun C, Joseph BK, Gallo-Ebert C, et al. Identifi cation of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J Lipid Res. 2014;55:226-38
31. Zhu DQ, Lou YF, He ZG, Ji M. Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a. Tumour Biol. 2014; 35:11829-35
32. Zhong D, Zhang Y, Zeng YJ, Gao M, Wu GZ, Hu CJ, et al. MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRalpha. Lipids Health Dis. 2013;12:32
33. Zhao R, Feng J, He G. miR-613 regulates cholesterol effl ux by targeting LXRalpha and ABCA1 in PPARgamma activated THP-1 macrophages. Biochem Biophys Res Commun. 2014;448:329-34
34. Miller AM, Gilchrist DS, Nijjar J, Araldi E, Ramirez CM, Lavery CA, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One. 2013;8, e72324
35. Vinod M, Chennamsetty I, Colin S, Belloy L, De Paoli F, Schaider H, et al. miR-206 controls LXRalpha expression and promotes LXR-mediated cholesterol effl ux in macrophages. Biochim Biophys Acta. 2014;1841:827-35
36. Ou Z, Wada T, Gramignoli R, Li S, Strom SC, Huang M, et al. MicroRNA hsa-miR-613 targets the human LXRalpha gene and mediates a feedback loop of LXRalpha autoregulation. Mol Endocrinol. 2011;25:584-96
37. Walker AK, Yang F, Jiang K, Ji JY, Watts JL, Purushotham A, et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 2010;24:1403-17
38. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28:91-106
39. Yu J, Auwerx J. Protein deacetylation by SIRT1: an emerging key post-translational modifi - cation in metabolic regulation. Pharmacol Res. 2010;62:35-41
40. Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 2010;285: 33959-70
41. Xiong H, Pang J, Yang H, Dai M, Liu Y, Ou Y, et al. Activation of miR-34a/SIRT1/p53 signaling contributes to cochlear hair cell apoptosis: implications for age-related hearing loss. Neurobiol Aging. 2015;36(4):1692-701
42. Fan W, Fang R, Wu X, Liu J, Feng M, Dai G, et al. Shear-sensitive microRNA-34a modulates fl ow-dependent regulation of endothelial infl ammation. J Cell Sci. 2015;128:70-80
43. Zhang L, Huang D, Wang Q, Shen D, Wang Y, Chen B, et al. MiR-132 inhibits expression of SIRT1 and induces pro-infl ammatory processes of vascular endothelial infl ammation through blockade of the SREBP-1c metabolic pathway. Cardiovasc Drugs Ther. 2014;28:303-11
44. Gao J, Wang Y, Zhao X, Chen P, Xie L. MicroRNA-204-5p-mediated regulation of SIRT1 contributes to the delay of epithelial cell cycle traversal in diabetic corneas. Invest Ophthalmol Vis Sci. 2015;56:1493-504
45. Zhang H, Feng Z, Huang R, Xia Z, Xiang G, Zhang J. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol. 2014;45:2143-52
46. Duan JH, Fang L. MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR. Tumour Biol. 2014;35:11013-9
47. Zhang Y, Gong W, Dai S, Huang G, Shen X, Gao M, et al. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res. 2012;10:516-22
48. Lee CG, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ, et al. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology. 2012;142:1206-17. e7
49. Li J, Zhang Y, Kuruba R, Gao X, Gandhi CR, Xie W, et al. Roles of microRNA-29a in the antifi - brotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol. 2011;80: 191-200
50. de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldan A, Esau C, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013;112:1602-12
51. Oda Y, Nakajima M, Tsuneyama K, Takamiya M, Aoki Y, Fukami T, et al. Retinoid X receptor alpha in human liver is regulated by miR-34a. Biochem Pharmacol. 2014;90:179-87
52. Adlakha YK, Khanna S, Singh R, Singh VP, Agrawal A, Saini N. Pro-apoptotic miRNA- 128- 2 modulates ABCA1, ABCG1 and RXRalpha expression and cholesterol homeostasis. Cell Death Dis. 2013;4, e780
53. Hu Z, Shen WJ, Cortez Y, Tang X, Liu LF, Kraemer FB, et al. Hormonal regulation of microRNA expression in steroid producing cells of the ovary, testis and adrenal gland. PLoS One. 2013;8, e78040
54. Hu Z, Shen WJ, Kraemer FB, Azhar S. MicroRNAs 125a and 455 repress lipoproteinsupported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells. Mol Cell Biol. 2012;32:5035-45
55. Irani S, Hussain MM. Role of microRNA-30c in lipid metabolism, adipogenesis, cardiac remodeling and cancer. Curr Opin Lipidol. 2015;26:139-46
56. Chen KC, Hsieh IC, Hsi E, Wang YS, Dai CY, Chou WW, et al. Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1. J Cell Sci. 2011;124:4115-24
57. Loyer X, Mallat Z, Boulanger CM, Tedgui A. MicroRNAs as therapeutic targets in atherosclerosis. Expert Opin Ther Targets. 2015;19:489-96
58. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570-3
59. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A. 2010;107:12228-32
60. Najafi -Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328: 1566-9
61. Allen RM, Marquart TJ, Jesse JJ, Baldan A. Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33. Circ Res. 2014;115:10-22
62. Marquart TJ, Wu J, Lusis AJ, Baldan A. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-defi cient mice. Arterioscler Thromb Vasc Biol. 2013;33:455-8
63. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404-7
64. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921-31
65. Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med. 2012;4:882-95
66. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 defi ciency reduces the progression of atherosclerotic plaque in ApoE−/− mice. J Am Heart Assoc. 2012;1, e003376
67. Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr−/− mice-brief report. Arterioscler Thromb Vasc Biol. 2013;33:1973-7
68. Fernandez-Hernando C, Moore KJ. MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol. 2011;31:2378-82
69. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A. 2011;108:9232-7
70. Ramirez CM, Goedeke L, Rotllan N, Yoon JH, Cirera-Salinas D, Mattison JA, et al. MicroRNA 33 regulates glucose metabolism. Mol Cell Biol. 2013;33:2891-902
71. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55:2565-82
72. Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, et al. miR- 33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes. 2012;61:653-8
73. Chen WJ, Zhang M, Zhao GJ, Fu Y, Zhang DW, Zhu HB, et al. MicroRNA-33 in atherosclerosis etiology and pathophysiology. Atherosclerosis. 2013;227:201-8
74. Iwakiri Y. A role of miR-33 for cell cycle progression and cell proliferation. Cell Cycle. 2012; 11:1057-8
75. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, et al. miR- 33- mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle. 2010;9:3277-85
76. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. miR-122, a mammalian liverspecifi c microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1:106-13
77. Li ZY, Xi Y, Zhu WN, Zeng C, Zhang ZQ, Guo ZC, et al. Positive regulation of hepatic miR- 122 expression by HNF4alpha. J Hepatol. 2011;55:602-11
78. Gatfi eld D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 2009;23:1313-26
79. Katoh T, Sakaguchi Y, Miyauchi K, Suzuki T, Kashiwabara S, Baba T. Selective stabilization of mammalian microRNAs by 3’ adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. Genes Dev. 2009;23:433-8
80. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685-9
81. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008; 36:1153-62
82. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, antiinfl ammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122: 2871-83
83. Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C. microRNAs and cholesterol metabolism. Trends Endocrinol Metab. 2010;21:699-706
84. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 2010;6:402
85. de Jong YP, Jacobson IM. Antisense therapy for hepatitis C virus infection. J Hepatol. 2014;60:227-8
86. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685-94
87. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specifi c MicroRNA. Science. 2005;309:1577-81
88. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198-201
89. Wang R, Hong J, Cao Y, Shi J, Gu W, Ning G, et al. Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults. Eur J Endocrinol. 2015;172:291-300
90. Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5): 800-12
91. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and infl ammation in alcoholic, drug-induced, and infl ammatory liver diseases. Hepatology. 2012;56:1946-57
92. Gao W, He HW, Wang ZM, Zhao H, Lian XQ, Wang YS, et al. Plasma levels of lipometabolismrelated miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis. 2012;11:55
93. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008; 451:1125-9
94. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005;123:819-31
95. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y, et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profi ling. Cell. 2007;129:617-31
96. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A. 2014;111: 14518-23
97. Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si SY, et al. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol. 2013;33:1956-64
98. Pan Y, Liang H, Liu H, Li D, Chen X, Li L, et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin- like growth factor 1 receptor. J Immunol. 2014;192:437-46
99. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423-33
100. Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, et al. HDLtransferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun. 2014;5:3292
101. Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sasaki M, et al. Administration of high dose eicosapentaenoic acid enhances anti-infl ammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis. 2014;237:577-83
102. Sang H, Yao S, Zhang L, Li X, Yang N, Zhao J, et al. Walk-run training improves the antiinfl ammation properties of high-density lipoprotein in patients with metabolic syndrome. J Clin Endocrinol Metab. 2015;100:870-9
103. Song GJ, Kim SM, Park KH, Kim J, Choi I, Cho KH. SR-BI mediates high density lipoprotein (HDL)-induced anti-infl ammatory effect in macrophages. Biochem Biophys Res Commun. 2015;457:112-8
104. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Antiinfl ammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-67
105. Gong M, Wilson M, Kelly T, Su W, Dressman J, Kincer J, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest. 2003;111:1579-87
106. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 infl ammasome activity is negatively controlled by miR-223. J Immunol. 2012;189:4175-81
107. Weber C, Soehnlein O. ApoE controls the interface linking lipids and infl ammation in atherosclerosis. J Clin Invest. 2011;121:3825-7
108. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and infl ammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008;118:183-94
109. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boilard E, et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood. 2013;122:253-61
110. Aucher A, Rudnicka D, Davis DM. MicroRNAs transfer from human macrophages to hepato- carcinoma cells and inhibit proliferation. J Immunol. 2013;191:6250-60
111. Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H, et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue infl ammation. Circulation. 2012;125: 2892-903
112. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res. 2010;86:410-20
113. Shi R, Ge L, Zhou X, Ji WJ, Lu RY, Zhang YY, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res. 2013;131:508-13
114. Zhang YY, Zhou X, Ji WJ, Shi R, Lu RY, Li JL, et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis. 2014;38:65-72
115. Chyrchel B, Toton-Zuranska J, Kruszelnicka O, Chyrchel M, Mielecki W, Kolton-Wroz M, et al. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. Platelets. 2015;26(6):593-7. doi: 10.3109/09537104.2014.974527
116. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012;60: 290-9
117. Liverani E, Kilpatrick LE, Kunapuli SP. P2Y12 receptor in cardiovascular disease. J Cardiovasc Dis. 2014;2:203-8
118. Shameem R, Hamid MS, Randahawa A, Spaccavento C, Garatt K. P2Y12 antagonists: pharmacology, effi cacy, and patient consideration. J Cardiovasc Dis. 2014;2:91-100
119. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, Fukami T, et al. PPARalpha is regulated by miR-21 and miR-27b in human liver. Pharm Res. 2011;28:2467-76
120. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol. 2013;87:5270-86
121. Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009;205:413-9
122. Liu Y, Berendsen AD, Jia S, Lotinun S, Baron R, Ferrara N, et al. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest. 2012;122:3101-13
123. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J. 2009;276:2348-58
124. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, et al. MicroRNA- 27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology. 2013;57:533-42
125. Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol. 2014;5:4
126. Galhardo M, Sinkkonen L, Berninger P, Lin J, Sauter T, Heinaniemi M. Integrated analysis of transcript-level regulation of metabolism reveals disease-relevant nodes of the human metabolic network. Nucleic Acids Res. 2014;42:1474-96
127. Wang L, Ye X, Liu Y, Wei W, Wang Z. Aberrant regulation of FBW7 in cancer. Oncotarget. 2014;5:2000-15
128. Singaravelu R, Chen R, Lyn RK, Jones DM, O’Hara S, Rouleau Y, et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology. 2014;59:98-108
129. Zhang M, Wu JF, Chen WJ, Tang SL, Mo ZC, Tang YY, et al. MicroRNA-27a/b regulates cellular cholesterol effl ux, infl ux and esterifi cation/hydrolysis in THP-1 macrophages. Atherosclerosis. 2014;234:54-64
130. Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest. 2002;82:273-83
131. Wang D, Xia M, Yan X, Li D, Wang L, Xu Y, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res. 2012;111:967-81
132. Lv YC, Tang YY, Peng J, Zhao GJ, Yang J, Yao F, et al. MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1. Atherosclerosis. 2014;236:215-26
133. Sun D, Zhang J, Xie J, Wei W, Chen M, Zhao X. MiR-26 controls LXR-dependent cholesterol effl ux by targeting ABCA1 and ARL7. FEBS Lett. 2012;586:1472-9
134. Ma Y, Li X, Cheng S, Wei W, Li Y. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol Med Rep. 2015;11:625-32
135. Kim J, Yoon H, Ramirez CM, Lee SM, Hoe HS, Fernandez-Hernando C. MiR-106b impairs cholesterol effl ux and increases Abeta levels by repressing ABCA1 expression. Exp Neurol. 2012;235:476-83
136. Kang MH, Zhang LH, Wijesekara N, de Haan W, Butland S, Bhattacharjee A, et al. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol. 2013;33:2724-32
137. Sala F, Aranda JF, Rotllan N, Ramirez CM, Aryal B, Elia L, et al. MiR-143/145 defi ciency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost. 2014;112:796-802
138. Ramirez CM, Rotllan N, Vlassov AV, Davalos A, Li M, Goedeke L, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 2013;112:1592-601
139. Hu YW, Hu YR, Zhao JY, Li SF, Ma X, Wu SG, et al. An agomir of miR-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting proinfl ammatory cytokine production. PLoS One. 2014;9, e94997
140. Meiler S, Baumer Y, Toulmin E, Seng K, Boisvert WA. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:323-31
141. Ramirez CM, Davalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, et al. MicroRNA-758 regulates cholesterol effl ux through posttranscriptional repression of ATPbinding cassette transporter A1. Arterioscler Thromb Vasc Biol. 2011;31:2707-14
142. Mandolini C, Santovito D, Marcantonio P, Buttitta F, Bucci M, Ucchino S, et al. Identifi cation of microRNAs 758 and 33b as potential modulators of ABCA1 expression in human atherosclerotic plaques. Nutr Metab Cardiovasc Dis. 2015;25:202-9
143. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high target-site abundance decrease the profi ciency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011;18:1139-46
144. Benatti RO, Melo AM, Borges FO, Ignacio-Souza LM, Simino LA, Milanski M, et al. Maternal high-fat diet consumption modulates hepatic lipid metabolism and microRNA-122 (miR-122) and microRNA-370 (miR-370) expression in offspring. Br J Nutr. 2014;111:2112-22
145. Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics. 2013;14:1517-26